Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization after Antenatal Messenger RNA Vaccination

Amihai Rottenstreich, Olesya Vorontsov, Or Alfi, Gila Zarbiv, Esther Oiknine-Djian, Roy Zigron, Geffen Kleinstern, Michal Mandelboim, Shay Porat, Dana G. Wolf*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

We evaluated the neutralization efficiency against SARS-CoV-2 Omicron variant in maternal and cord blood sera after antenatal BNT162b2 vaccination. Neutralizing antibodies against Omicron were lacking at the time of delivery after 2-dose vaccination. A third booster dose was essential in building neutralizing antibody capacity against Omicron among mothers and neonates.

Original languageAmerican English
Pages (from-to)2023-2026
Number of pages4
JournalClinical Infectious Diseases
Volume75
Issue number11
DOIs
StatePublished - 1 Dec 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Keywords

  • COVID-19
  • Omicron
  • SARS-CoV-2
  • pregnancy
  • vaccination

Fingerprint

Dive into the research topics of 'Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization after Antenatal Messenger RNA Vaccination'. Together they form a unique fingerprint.

Cite this